CD274 and hepatocellular carcinoma: Furthermore, the efficacy and safety of immune checkpoint inhibitors, including pembrolizumab and camrelizumab, that inhibit immune escape through the PD‐1/PD‐L1 axis have been demonstrated for advanced HCC in multiple previous trials, which seems to inhibit the consequences of tumor escape caused by traditional treatment, thus playing a complementary role.29, 61